Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform, TargoSphere®.
Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells.RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 17, 2013 | Series Unknown | €2.60M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ERP Startfonds | — | Series Unknown |